BRPI0519349A2 - prevenÇço de formaÇço e/ou estabilizaÇço de trombos - Google Patents
prevenÇço de formaÇço e/ou estabilizaÇço de trombosInfo
- Publication number
- BRPI0519349A2 BRPI0519349A2 BRPI0519349-4A BRPI0519349A BRPI0519349A2 BR PI0519349 A2 BRPI0519349 A2 BR PI0519349A2 BR PI0519349 A BRPI0519349 A BR PI0519349A BR PI0519349 A2 BRPI0519349 A2 BR PI0519349A2
- Authority
- BR
- Brazil
- Prior art keywords
- stabilization
- prevention
- formation
- thrombi
- factor xii
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/556—Angiotensin converting enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/56—Protease inhibitors from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Botany (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
PREVENÇçO DE FORMAÇçO E/OU ESTABILIZAÇçO DE TROMBOS. A presente invenção refere-se ao uso de pelo menos um anti-corpo e/ou um inibidor para inibir o fator XII e prevenir a formação e/ou estabilização de trombos tridimensionais. Ela refere-se também a uma formulação farmacêutico e ao uso do fator XII como um alvo antitrombótico.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04030593 | 2004-12-23 | ||
PCT/EP2005/013714 WO2006066878A1 (en) | 2004-12-23 | 2005-12-20 | Prevention of thrombus formation and/or stabilization |
Publications (2)
Publication Number | Publication Date |
---|---|
BRPI0519349A2 true BRPI0519349A2 (pt) | 2009-01-20 |
BRPI0519349A8 BRPI0519349A8 (pt) | 2017-09-12 |
Family
ID=34927953
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0519349A BRPI0519349A8 (pt) | 2004-12-23 | 2005-12-20 | Prevenção de formação e/ou estabilização de trombos |
Country Status (14)
Country | Link |
---|---|
US (3) | US8119137B2 (pt) |
EP (2) | EP2272565A3 (pt) |
JP (1) | JP5118492B2 (pt) |
KR (1) | KR101277097B1 (pt) |
CN (1) | CN101102819A (pt) |
AU (1) | AU2005318464B2 (pt) |
BR (1) | BRPI0519349A8 (pt) |
CA (1) | CA2591786C (pt) |
DK (1) | DK1830924T3 (pt) |
ES (1) | ES2407965T3 (pt) |
MX (1) | MX2007006997A (pt) |
PL (1) | PL1830924T3 (pt) |
RU (1) | RU2514878C2 (pt) |
WO (1) | WO2006066878A1 (pt) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
US7153829B2 (en) | 2002-06-07 | 2006-12-26 | Dyax Corp. | Kallikrein-inhibitor therapies |
WO2003103475A2 (en) | 2002-06-07 | 2003-12-18 | Dyax Corp. | Prevention and reduction of blood loss |
US7166576B2 (en) | 2002-08-28 | 2007-01-23 | Dyax Corp. | Methods for preserving organs and tissues |
US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
GB0607515D0 (en) * | 2006-04-13 | 2006-05-24 | Axis Shield Diagnostics Ltd | Anti-factor xlla therapy |
AU2007281220B2 (en) | 2006-07-31 | 2013-08-15 | Activesite Pharmaceuticals, Inc. | Inhibitors of plasma kallikrein |
DK2526962T3 (da) | 2007-02-12 | 2019-10-07 | Csl Behring Gmbh | Therapeutic application of Kazal-type serine protease inhibitors |
CA2695012A1 (en) * | 2007-08-23 | 2009-02-26 | Genzyme Corporation | Treatment with kallikrein inhibitors |
CA2703264A1 (en) * | 2007-10-22 | 2009-04-30 | Georg Dewald | Disorders of vasoregulation and methods of diagnosing them |
EP2145900A1 (en) | 2008-07-15 | 2010-01-20 | CSL Behring GmbH | Orai1 (CRACM1) is the platelet SOC channel and essential for pathological thrombus formation |
EP2103311A1 (en) | 2008-03-20 | 2009-09-23 | CSL Behring GmbH | The calcium sensor STIM1 is essential for pathological thrombus formation |
AU2010203712A1 (en) | 2009-01-06 | 2010-07-15 | Dyax Corp. | Treatment of mucositis with kallikrein inhibitors |
EP2269597A1 (en) | 2009-06-22 | 2011-01-05 | CSL Behring GmbH | CLEC-2 is an essential platelet activating receptor in hemostasis and thrombosis |
EP2272874A1 (en) | 2009-07-10 | 2011-01-12 | CSL Behring GmbH | Role of PLD1 in thrombus formation and integrin alpha IIb beta 3 activation |
PT2521568T (pt) | 2010-01-06 | 2018-10-26 | Dyax Corp | Proteínas de ligação à calicreína plasmática |
EP2371857A1 (en) * | 2010-04-01 | 2011-10-05 | CSL Behring GmbH | Factor XII inhibitors for treating interstitial lung disease |
US9150864B2 (en) * | 2010-11-08 | 2015-10-06 | Isis Pharmaceuticals, Inc. | Methods for modulating factor 12 expression |
KR102011156B1 (ko) | 2011-01-06 | 2019-08-16 | 다이액스 코포레이션 | 혈장 칼리크레인 결합 단백질 |
EP2497489A1 (en) | 2011-03-09 | 2012-09-12 | CSL Behring GmbH | Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs |
PL2683397T3 (pl) | 2011-03-09 | 2018-01-31 | Csl Behring Gmbh | Inhibitory czynnika XII do podawania w zabiegach medycznych obejmujących kontakt z powierzchniami sztucznymi |
US9187749B2 (en) | 2011-06-10 | 2015-11-17 | Isis Pharmaceuticals, Inc. | Methods for modulating factor 12 expression |
IL230564B2 (en) | 2011-07-22 | 2023-09-01 | Csl Ltd | Anticoagulant monoclonal antibodies anti–factor xii/fxiia, a method for their preparation, a pharmaceutical compound containing them and medical uses. |
EP2548892A1 (en) | 2011-07-22 | 2013-01-23 | CSL Behring GmbH | Inhibitory anti-Factor XII/XIIa monoclonal Antibodies and their uses |
JP6491880B2 (ja) * | 2011-08-23 | 2019-03-27 | シナプス・ビー.ブイ.Synapse B.V. | 異物表面との接触による血液凝固系の活性化の熱安定性阻害剤 |
EP2623110A1 (en) * | 2012-01-31 | 2013-08-07 | CSL Behring GmbH | Factor XII inhibitors for the treatment of neurological inflammatory disorders |
US9574013B2 (en) * | 2012-12-07 | 2017-02-21 | Vanderbilt University | Antibodies against factor XII and uses thereof |
KR102403299B1 (ko) | 2013-03-08 | 2022-06-03 | 체에스엘 베링 게엠베하 | 원격 허혈-재관류 손상의 치료 및 예방 |
CN105339010A (zh) * | 2013-06-28 | 2016-02-17 | 德国杰特贝林生物制品有限公司 | 使用因子xii抑制剂和c1-抑制剂的联合疗法 |
DK3157548T3 (da) | 2014-06-18 | 2021-09-06 | Csl Behring Gmbh | Terapi anvendelse af en faktor xii-inhibitor i en neurotraumatisk sygdom |
EA201791527A1 (ru) | 2015-01-02 | 2017-12-29 | Дайэкс Корп. | Биспецифические антитела против плазменного калликреина и фактора xii |
EP3288962A1 (en) * | 2015-04-28 | 2018-03-07 | Ecole Polytechnique Fédérale de Lausanne (EPFL) | Novel inhibitors of the enzyme activated factor xii (fxiia) |
EA201890340A1 (ru) | 2015-07-21 | 2018-09-28 | Дайэкс Корп. | Моноклональное антитело-ингибитор фактора xiia |
US11286307B2 (en) | 2015-12-11 | 2022-03-29 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
JP7456723B2 (ja) * | 2016-04-06 | 2024-03-27 | シーエスエル、リミテッド | アテローム性動脈硬化症の治療方法 |
WO2019113642A1 (en) | 2017-12-15 | 2019-06-20 | Csl Limited | Use of a fxiia-inhibitor in the treatment of renal fibrosis and/or chronic kidney disease |
WO2019246176A1 (en) | 2018-06-19 | 2019-12-26 | Regeneron Pharmaceuticals, Inc. | Anti-factor xii/xiia antibodies and uses thereof |
US20220089776A1 (en) * | 2018-11-28 | 2022-03-24 | Oregon Health & Science University | Therapeutic factor xii antibody |
CN114502531B (zh) | 2019-07-08 | 2024-05-24 | 雷佐鲁特公司 | 制备血浆激肽释放酶抑制剂的方法 |
JP7088892B2 (ja) | 2019-10-11 | 2022-06-21 | イビデン株式会社 | 組電池用断熱シート及び組電池 |
US20230295343A1 (en) * | 2020-06-16 | 2023-09-21 | Ningbo Comgen Biotech Co., Ltd. | Anti-factor xii (fxii) nanobody or antigen-binding fragment thereof, and use thereof |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK225488D0 (da) * | 1988-04-26 | 1988-04-26 | Novo Industri As | Polypeptid |
US4963657A (en) * | 1988-06-09 | 1990-10-16 | Temple University Of The Commonwealth System Of Higher Education | Monoclonal antibodies to the light chain region of human factor XII and methods of preparing and using the same |
WO1994020535A1 (en) | 1992-12-11 | 1994-09-15 | Corvas International, Inc. | ECOTIN AS A FACTOR Xa, XIa, AND XIIa INHIBITOR |
EP0719334A1 (en) | 1993-09-14 | 1996-07-03 | Genentech, Inc. | Pharmaceutical compositions containing ecotin and homologs thereof |
ZA963619B (en) * | 1995-05-08 | 1996-11-22 | Scios Inc | Protease inhibitor peptides |
US20030109680A1 (en) | 2001-11-21 | 2003-06-12 | Sunol Molecular Corporation | Antibodies for inhibiting blood coagulation and methods of use thereof |
DE19725014A1 (de) * | 1997-06-13 | 1998-12-17 | Bayer Ag | Aprotininvarianten mit verbesserten Eigenschaften und Bikunine von Aprotininvarianten |
GB9800817D0 (en) | 1998-01-16 | 1998-03-11 | Bio Discovery Ltd | Serine protease inhibitors |
AU757459B2 (en) * | 1998-06-08 | 2003-02-20 | University Of Vermont And State Agricultural College, The | Inhibition of coagulation in blood and blood products |
WO2000018352A2 (en) * | 1998-09-28 | 2000-04-06 | Merck & Co., Inc. | A method for treating inflammatory diseases by administering a thrombin inhibitor |
ATE468136T1 (de) * | 2001-01-11 | 2010-06-15 | D Collen Res Foundation Vzw | Verfahren und pharmazeutische zusammensetzung zur vorbeugung und/oder behandlung des syndroms der systemischen entzündlichen reaktion |
WO2003103475A2 (en) * | 2002-06-07 | 2003-12-18 | Dyax Corp. | Prevention and reduction of blood loss |
US7153829B2 (en) * | 2002-06-07 | 2006-12-26 | Dyax Corp. | Kallikrein-inhibitor therapies |
US20060093595A1 (en) | 2002-07-05 | 2006-05-04 | Mahesh Jayachandra | Methods, compositions and kits for treating damage to excitable tissue |
US7166576B2 (en) * | 2002-08-28 | 2007-01-23 | Dyax Corp. | Methods for preserving organs and tissues |
US20040229778A1 (en) | 2003-05-13 | 2004-11-18 | Elmaleh David R. | Pharmaceutical compositions of antithrombin III for the treatment of retroviral diseases |
WO2004110356A2 (en) | 2003-05-15 | 2004-12-23 | Cbr Institute For Biomedical Research, Inc. | Methods for modulating cell-to-cell adhesion using an agonist of c1inh-type protein activity |
DK1626736T3 (da) | 2003-05-16 | 2020-09-28 | Pharming Intellectual Property B V | C1-inhibitor med kort halveringstid til midlertidig behandling |
US8152750B2 (en) | 2003-09-12 | 2012-04-10 | Marine Polymer Technologies, Inc. | Vascular access preservation in hemodialysis patients |
GB0411145D0 (en) | 2004-05-19 | 2004-06-23 | Imp College Innovations Ltd | Protease inhibitors and their therapeutic applications |
US8569277B2 (en) | 2004-08-11 | 2013-10-29 | Palo Alto Investors | Methods of treating a subject for a condition |
GB0418877D0 (en) | 2004-08-24 | 2004-09-29 | Univ Edinburgh | Heart |
US20060104944A1 (en) | 2004-11-18 | 2006-05-18 | Mousa Shaker A | Activators and inhibitors of protease activated receptor2 (PAR2) and methods of use |
ATE469650T1 (de) | 2004-12-01 | 2010-06-15 | Par Pharmaceuticals Inc | Verwendung von megestrolacetat zur verbesserung der herzfunktion und zur behandlung von herzinsuffizienz |
-
2005
- 2005-12-20 KR KR1020077016992A patent/KR101277097B1/ko active IP Right Grant
- 2005-12-20 MX MX2007006997A patent/MX2007006997A/es active IP Right Grant
- 2005-12-20 EP EP10183075A patent/EP2272565A3/en not_active Withdrawn
- 2005-12-20 PL PL05820601T patent/PL1830924T3/pl unknown
- 2005-12-20 RU RU2007123797/14A patent/RU2514878C2/ru not_active Application Discontinuation
- 2005-12-20 AU AU2005318464A patent/AU2005318464B2/en active Active
- 2005-12-20 DK DK05820601.2T patent/DK1830924T3/da active
- 2005-12-20 JP JP2007547323A patent/JP5118492B2/ja active Active
- 2005-12-20 EP EP05820601A patent/EP1830924B1/en active Active
- 2005-12-20 CA CA2591786A patent/CA2591786C/en active Active
- 2005-12-20 ES ES05820601T patent/ES2407965T3/es active Active
- 2005-12-20 WO PCT/EP2005/013714 patent/WO2006066878A1/en active Application Filing
- 2005-12-20 CN CNA2005800465756A patent/CN101102819A/zh active Pending
- 2005-12-20 BR BRPI0519349A patent/BRPI0519349A8/pt not_active Application Discontinuation
- 2005-12-20 US US11/793,820 patent/US8119137B2/en active Active
-
2011
- 2011-12-29 US US13/339,793 patent/US20120148688A1/en not_active Abandoned
-
2012
- 2012-12-21 US US13/723,847 patent/US8715672B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
BRPI0519349A8 (pt) | 2017-09-12 |
CA2591786C (en) | 2013-07-16 |
PL1830924T3 (pl) | 2013-08-30 |
RU2514878C2 (ru) | 2014-05-10 |
EP1830924A1 (en) | 2007-09-12 |
US20120148688A1 (en) | 2012-06-14 |
WO2006066878A1 (en) | 2006-06-29 |
KR20070092303A (ko) | 2007-09-12 |
MX2007006997A (es) | 2007-10-10 |
EP1830924B1 (en) | 2013-02-27 |
AU2005318464B2 (en) | 2012-02-23 |
JP5118492B2 (ja) | 2013-01-16 |
EP2272565A2 (en) | 2011-01-12 |
KR101277097B1 (ko) | 2013-06-20 |
DK1830924T3 (da) | 2013-05-21 |
US8715672B2 (en) | 2014-05-06 |
EP2272565A3 (en) | 2012-03-28 |
ES2407965T3 (es) | 2013-06-17 |
AU2005318464A1 (en) | 2006-06-29 |
US20130164301A1 (en) | 2013-06-27 |
US8119137B2 (en) | 2012-02-21 |
US20080254039A1 (en) | 2008-10-16 |
JP2008525342A (ja) | 2008-07-17 |
CA2591786A1 (en) | 2006-06-29 |
RU2007123797A (ru) | 2009-01-10 |
CN101102819A (zh) | 2008-01-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0519349A2 (pt) | prevenÇço de formaÇço e/ou estabilizaÇço de trombos | |
WO2007019251A3 (en) | Sphingosine kinase inhibitors and methods of their use | |
BR112014004444A2 (pt) | composições e métodos que compreendem uma variante de enzima lipolítica | |
CL2007001388A1 (es) | Co-cristal de maleato de 2{etil[3-({4-[(5-{2-[(3-fluorfenil)amino]-2-oxoetil}-1h-pirazol-3-il)amino]quinazolin-7-il}oxi)propil]amino}fosfato dihidrogeno de etilo (azd1152), inhibidor de aurora quinasa; metodo de preparacion; composicion farmaceutica; y uso para el tratamiento de enfermedades hiperproliferativas como el cancer. | |
BRPI0512622A (pt) | uso de compostos de peptìdeos para tratamento de tremor e outras sìndromes de tremor | |
WO2008048801A3 (en) | Phenylalkylamino carbamate compositions | |
BRPI0414066A (pt) | 42-éster de rapamicina amorfo com ácido 3-hidróxi-2-( hidroximetil )-2-metilproipiÈnico e composições farmacêuticas que o contenha | |
EP2666472A3 (en) | Uses and compositions for treatment of psoriatic arthritis | |
NI200800299A (es) | Compuestos de triazolopirazina utiles para el tratamiento de enfermedades degenerativas e inflamatorias. | |
BRPI0511291A (pt) | uso de compostos de peptìdeo para tratar discinesia | |
WO2008070593A3 (en) | Variant target binding agents and uses thereof | |
UY29376A1 (es) | Anilidas de ácido pirazolcarboxílico, un procedimiento para su obtencón y productos que contienen las mismas para combatir hongos nocivos. | |
WO2016127019A3 (en) | Pharmaceutical compositions for combination therapy | |
EA200802118A1 (ru) | Обладающие ингибирующей активностью в отношении mnk1/mnk2 тиенопиримидины, предназначенные для применения в фармацевтических композициях | |
WO2007093183A3 (en) | Use of a compound that enhances gabaa-ergic neurotransmission for the treatment of inflammatory diseases | |
ECSP077401A (es) | Medicamentos que contienen compuestos de carbonilo y su uso | |
DE602006015963D1 (de) | Immunstimulatorisches verfahren | |
UY30468A1 (es) | Compuestos quimicos. | |
DOP2007000053A (es) | Compuestos de tetrahidropiridotienopirimidina y métodos para su empleo | |
ATE529430T1 (de) | Caspase-hemmer-propharmaka | |
WO2006114439A3 (en) | Novel nutraceutical compositions | |
EP1938691A3 (en) | Nematicidal compositions | |
CL2007002384A1 (es) | Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis. | |
WO2007005672A3 (en) | Treatment and prevention of respiratory diseases and conditions | |
WO2009051718A3 (en) | Calcium receptor modulating agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B15K | Others concerning applications: alteration of classification |
Ipc: A61K 39/395 (2006.01), A61P 7/02 (2006.01), A61K 3 |
|
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL |